Dopamine-Blocking Antipsychotics—Time for a New Conversation With Patients?

This Viewpoint discusses what the role of dopamine blockers and non–dopamine-blocking antipsychotics may have in psychiatric practice.

Corresponding Author: Stephen R. Marder, MD, University of California Los Angeles David Geffen School of Medicine, Bldg 206, Room 118 West Los Angeles VA HCC, 11301 Wilshire Blvd, Los Angeles, CA 90073 (marder@ucla.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.